Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients
Glenn F. van Wigcheren, Nienke de Haas, Tom A. Mulder, Sophie K. Horrevorts, Martine Bloemendal, Simone Hins-Debree, Yumeng Mao, Rolf Kiessling, Carla M.L. van Herpen, Georgina Flórez‐Grau, Stanleyson V. Hato, I. Jolanda M. de Vries
Abstract
and in cancer patients. Therefore, platinum-based drugs have the potential to enhance response rates of immunotherapy by overcoming M-MDSC-mediated immunosuppression.
Topics & Concepts
MedicineCisplatinCancer researchMyeloid-derived Suppressor CellImmunotherapyCancerMelanomaImmunologyCancer immunotherapyInternal medicineChemotherapySuppressorImmune cells in cancerImmune Response and InflammationCancer Immunotherapy and Biomarkers